01OverviewDefinition, clinical context and the essential points that orientate the chapter.
Superficial vein thrombosis (SVT), historically called superficial thrombophlebitis, is thrombus with inflammation in a superficial vein. It commonly develops within varicose tributaries or incompetent great or small saphenous veins, although trauma, an intravenous cannula, inflammation, thrombophilia and malignancy are alternative contexts. The classic tender, erythematous, palpable cord is clinically recognisable, but its visible length underestimates the anatomical problem. The key risks are unsuspected DVT, extension through the saphenofemoral or saphenopopliteal junction, and pulmonary embolism. This is why whole-leg duplex, not clinical inspection alone, determines treatment.
Management depends on three measurements: whether DVT is present, the shortest distance from thrombus to a deep venous junction, and total SVT length. ESVS recommends therapeutic anticoagulation when thrombus is less than 3 cm from a deep junction and recommends fondaparinux 2.5 mg once daily for 45 days when it is at least 3 cm away and at least 5 cm long. The current UK Arixtra licence is narrower: it requires the thrombus to be more than 3 cm from the saphenofemoral junction. Therefore an exact 3 cm measurement, particularly at that junction, is a specialist anticoagulant-selection boundary rather than an automatic licensed fondaparinux case. High-risk clinical or anatomical features may support treatment for three months, but that extension has weaker evidence.
Key points
- Suspected lower-limb superficial vein thrombosis needs whole-leg duplex to measure extent and junction distance and to exclude asymptomatic, non-contiguous or contralateral DVT.
- ESVS places SVT less than 3 cm from a deep venous junction in the therapeutic anticoagulation branch; exactly 3 cm is a specialist product-scope boundary, not an automatic fondaparinux prescription.
- For isolated SVT at least 5 cm long and at least 3 cm from a deep junction, ESVS recommends fondaparinux 2.5 mg subcutaneously once daily for 45 days; the UK Arixtra licence is stricter and requires more than 3 cm from the saphenofemoral junction.
- Before fondaparinux, calculate creatinine clearance, assess bleeding, weight and pregnancy: the UK SmPC contraindicates CrCl below 20 mL/min, reduces dose to 1.5 mg daily at 20–50, and does not recommend SVT treatment below 50 kg.
- A short segment under 5 cm without cancer, thrombophilia or proximity to the deep system does not routinely need anticoagulation; provide symptom care and safety-net for extension or VTE.
- Extensive or recurrent SVT, thigh-level GSV or popliteal-fossa SSV disease, cancer, thrombophilia or other high-risk anatomy may justify a three-month anticoagulation plan after specialist risk assessment.
- Antibiotics do not treat uncomplicated SVT: warmth and erythema arise from sterile inflammation unless separate clinical evidence supports infection.
02AetiologyUnderlying causes, associations and risk factors, with why each one matters.
Venous stasis
Most spontaneous leg SVT forms in varicosities or an incompetent saphenous trunk, where dilatation and sluggish flow promote local thrombus.
Endothelial injury
Cannulation, sclerotherapy, trauma or procedures can injure a normal superficial vein, creating a local inflammatory thrombus with a different evidence base from spontaneous disease.
Systemic thrombophilia
Cancer, inherited or acquired thrombophilia and inflammatory disease become more relevant when SVT affects a normal vein, migrates, recurs or lacks an obvious local trigger.
03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.
- 1Superficial clot formation
Stasis, endothelial injury and hypercoagulability activate coagulation within a superficial vein, producing thrombus adherent to the venous wall.
- 2Sterile local inflammation
Perivenous inflammatory signalling causes pain, erythema, heat and induration; these appearances often mimic bacterial cellulitis despite absence of infection.
- 3Longitudinal extension
Thrombus can propagate along great or small saphenous pathways toward deep junctions, where entry into the deep circulation increases embolic risk.
- 4Concurrent thrombosis
A separate DVT may coexist in the same or opposite limb without continuity to the visible SVT, explaining the need for bilateral whole-leg imaging.
04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.
Typical SVT causes local pain, tenderness, erythema, heat and a firm linear or nodular cord along a superficial vein, often within pre-existing varicosities. Swelling may be local rather than affecting the entire limb.
Diffuse calf or whole-leg swelling, deep tenderness and collateral veins raise concern for DVT, yet many associated deep clots are clinically silent or not contiguous with the visible SVT.
Thigh-level great saphenous involvement, small saphenous thrombosis near the popliteal fossa, extensive length and proximity to a deep junction increase short-term thromboembolic concern.
Active cancer, thrombophilia, previous VTE, recurrent SVT, non-varicose-vein thrombosis, older age, recent hospitalisation and autoimmune disease can shift a short or otherwise borderline SVT toward anticoagulation assessment.
05InvestigationsWhat to request, why it matters and how to interpret it.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Bilateral whole-leg duplex ultrasoundFirst step - Why
- Confirm superficial thrombus, measure its full length and distance from deep junctions, and inspect deep veins for synchronous thrombosis.
- Interpretation and limitations
- Record vein and segment, centimetres from the saphenofemoral or saphenopopliteal junction, total length, DVT presence and reflux. These exact findings allocate the anticoagulation branch.
- 02
Creatinine clearance and baseline blood count - Why
- Assess suitability and dose for renally cleared anticoagulation and identify anaemia or thrombocytopenia before treatment.
- Interpretation and limitations
- For the current Arixtra SVT licence, CrCl below 20 mL/min is contraindicated and 20–50 mL/min requires 1.5 mg once daily, whose SVT safety and efficacy have not been studied.
- 03
Pregnancy assessment when relevant - Why
- Identify pregnancy because anticoagulant evidence, licensing and maternal-fetal considerations differ substantially.
- Interpretation and limitations
- The Arixtra SmPC states that adequate pregnancy data are absent and fondaparinux should be prescribed only if clearly necessary; obtain obstetric or haematology advice rather than extrapolating the routine SVT regimen.
- 04
Targeted provoking-factor work-up - Why
- Seek cancer, inflammatory disease or thrombophilia selectively in recurrent, migratory, unprovoked or non-varicose SVT.
- Interpretation and limitations
- A single provoked varicose-vein SVT does not mandate indiscriminate cancer or thrombophilia panels; recurrent unexplained events or systemic clues justify focused investigation.
06Differential diagnosisRealistic alternatives and the features that help distinguish them.
Cellulitis
Diffuse tender erythema without a venous cord, especially with fever or systemic illness, supports infection; SVT remains possible and imaging resolves uncertainty.
Deep vein thrombosis
Deep swelling and tenderness may dominate or be absent; whole-leg duplex distinguishes associated DVT because examination alone has insufficient sensitivity.
Ruptured Baker cyst
Sudden calf pain and swelling after posterior knee symptoms can mimic thrombosis, while ultrasound may identify fluid tracking and assess the veins.
Inflammatory nodules
Erythema nodosum, vasculitis and panniculitis produce tender lesions that do not follow a superficial venous trajectory and may have systemic associations.
Additional chapter-specific clues
Cellulitis is more diffuse and lacks a thrombosed cord; lymphangitis, abscess, erythema nodosum, vasculitis, ruptured Baker cyst and inflamed veins around an intravenous line require different management.
07ManagementImmediate care, first-line treatment, alternatives and escalation.
01Acute decision pathwayDuplex-defined lower-limb SVTFirst stepUse after a painful superficial cord is suspected and before choosing any anticoagulant intensity or duration.+
- 1Arrange bilateral whole-leg duplex to exclude DVT and record SVT vein, length and exact distance from the nearest deep venous junction.
- 2If DVT or PE is present, use the relevant VTE pathway; if SVT lies less than 3 cm from a deep junction, arrange therapeutic anticoagulation assessment.
- 3If isolated SVT is at least 5 cm long and at least 3 cm from the junction, apply ESVS guidance, then check UK product scope: use fondaparinux 2.5 mg subcutaneously once daily for 45 days only when the thrombus is more than 3 cm from the saphenofemoral junction and patient modifiers permit it; refer an exact 3 cm measurement for specialist selection.
- 4If SVT is shorter than 5 cm and has no high-risk feature, manage symptoms without routine anticoagulation and give explicit VTE and extension safety-netting.
- 5For extensive, recurrent, malignant, thrombophilic, thigh-level or other high-risk SVT, seek specialist advice about anticoagulation for up to three months.
02Safety pathwayFondaparinux prescribing checkUse before the first dose and whenever renal function, bleeding or procedures change during treatment.+
- 1Calculate creatinine clearance rather than relying on a laboratory eGFR alone; obtain full blood count and review active bleeding, lesions and concomitant antithrombotics.
- 2Use 2.5 mg subcutaneously once daily when CrCl exceeds 50 mL/min; at 20–50 mL/min the SmPC dose is 1.5 mg daily but SVT safety and efficacy are unstudied, so seek prescribing advice.
- 3Do not use when CrCl is below 20 mL/min, and do not use for SVT below 50 kg under the licence; pregnancy, severe hepatic impairment or high bleeding risk also require specialist selection.
- 4Teach injection technique and bleeding precautions; where possible omit fondaparinux during the 24 hours before surgery and restart at least six hours afterwards only after haemostasis.
03Recovery pathwayAfter acute inflammation settlesUse at follow-up when pain and erythema are resolving or when recurrent varicose-vein SVT remains a concern.+
- 1Confirm that symptoms are receding and reassess immediately for extension, new deep swelling, chest symptoms or bleeding.
- 2Review anticoagulant stop date and adherence; anti-inflammatory symptom relief does not replace the prescribed antithrombotic course.
- 3Refer suspected venous incompetence to a vascular service, and consider ablation only after the acute inflammatory and prothrombotic phase has settled, at least three months after the latest event.
Key medicines and prescribing safety1 treatment · regimens, roles and cautions+
Fondaparinux sodium
For eligible isolated lower-limb SVT, inject 2.5 mg subcutaneously once daily for 45 days; the UK licence permits a minimum 30 and maximum 45 days in high-risk patients.Contraindicated at CrCl below 20 mL/min; reduce to 1.5 mg daily at CrCl 20–50 though SVT evidence is unstudied. Not recommended for SVT below 50 kg or severe hepatic impairment; avoid active bleeding and use in pregnancy only if clearly necessary.
08ComplicationsImportant consequences, why they occur and why they matter clinically.
Deep vein thrombosis
SVT can extend through a junction or coexist with a separate deep clot, including asymptomatic calf and contralateral events.
Pulmonary embolism
Embolism may be present at diagnosis or develop during follow-up, so chest symptoms require emergency evaluation even when leg inflammation seems superficial.
Recurrent thrombosis
Ongoing varicose stasis, malignancy or thrombophilia can drive recurrent SVT and longer-term VTE risk after the acute episode resolves.
Anticoagulant bleeding
Renal accumulation, low body weight, older age, interacting drugs or an invasive procedure can convert preventive treatment into clinically important haemorrhage.
09Monitoring and follow-upTreatment response, safety checks and longer-term review.
- Reassess pain, erythema and cord extent; progression despite treatment or new proximal symptoms requires repeat clinical evaluation and often repeat duplex.
- Ask at every contact about unilateral deep swelling, breathlessness, pleuritic pain, haemoptysis, dizziness or collapse and escalate possible DVT or PE immediately.
- During fondaparinux, monitor clinically for bruising, haematuria, gastrointestinal bleeding and heavy menstrual bleeding; repeat blood count and renal function when baseline impairment or clinical change makes accumulation plausible.
- Verify injection technique, adherence and the documented 45-day stop date; clarify that missed or stopped doses should not be doubled without prescribing advice.
- At recovery, evaluate persistent varicose reflux and recurrent episodes; arrange vascular review after the acute phase rather than performing immediate superficial intervention.
10Special situationsVariants, exceptions and circumstances that change the usual approach.
Measure rather than estimate
Neither skin redness nor palpable-cord length reliably gives thrombus extent or junction distance. Duplex measurements control whether treatment is none, prophylactic-dose fondaparinux or therapeutic anticoagulation.
The three-centimetre boundary
ESVS assigns less than 3 cm to therapeutic anticoagulation and at least 3 cm to the fondaparinux branch, while the UK Arixtra licence requires more than 3 cm from the saphenofemoral junction. Exactly 3 cm therefore needs specialist product-scope assessment.
High risk can override length
A short segment may still merit anticoagulation assessment when cancer, thrombophilia, recurrence or junction proximity is present. Conversely, an uncomplicated short distal segment does not automatically need treatment.
Inflammation is usually sterile
Redness and warmth around a thrombosed superficial vein commonly prompt unnecessary antibiotics. Treat infection only when spreading inflammation, fever, purulence or systemic findings support it.
Licence and guideline differ
ESVS specifies 45 days for the standard anatomical group; the UK Arixtra SmPC describes 30–45 days in high-risk eligible patients and adds renal, weight, hepatic and pregnancy boundaries.
11Common pitfallsFrequent interpretation and management errors.
- 01
Diagnosing SVT clinically and omitting whole-leg duplex can miss a separate calf DVT, contralateral thrombosis or a dangerously close junctional extension.
- 02
Giving fondaparinux 2.5 mg daily for thrombus less than 3 cm from a deep junction undertreats the ESVS anatomy; giving it automatically at exactly 3 cm may exceed the UK product scope at the saphenofemoral junction.
- 03
Calling all warm erythema cellulitis leads to unnecessary antibiotics and fails to address thromboembolic risk.
- 04
Using an eGFR value without calculating creatinine clearance can misclassify a frail or low-weight patient before a renally cleared anticoagulant.
- 05
Treating every sub-5-cm SVT identically ignores the distinction between low-risk distal disease and cancer, thrombophilia, recurrence or junction proximity.
- 06
Scheduling acute ablation through an inflamed thrombosed segment conflicts with guidance to defer superficial intervention until the prothrombotic phase has settled.